Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –– High CRc rates (90–96%) ...
The province has introduced AI-driven software in health care to assist medical practitioners in notetaking and allowed the ...
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...
Compared with the recommended 4- to 7-day antibiotic course, a 1-day regimen achieved similar clinical cure rates, with no ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of ...
Pediatric data on tigecycline remain limited, particularly for multidrug-resistant infections caused by gram-negative ...
A chronic cough without heartburn are the tell-tale signs of the condition; surgery is typically not the answer.
As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.
It’s going to be a busy 4 days in Paris, with 166 late-breaking studies and nearly 2,000 clinical cases to be presented.
The study shows the heart team is “working,” say some, but one surgeon says TAVI use is still worryingly high in this group.
EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results